Common tumor metastasis sites and countermeasures after crizotinib resistance

Crizotinib, as an effective ALK inhibitor, plays an important role in the treatment of malignant tumors such as lung cancer. However, as treatment progresses, some patients may develop resistance to crizotinib, leading to disease progression and tumor metastasis. Understanding the common tumor metastasis sites and symptoms after drug resistance is of great significance for timely adjustment of treatment plans and improving patient prognosis.

When resistance to crizotinib occurs, tumors may metastasize to multiple sites. Common metastasis sites include the central nervous system (especially the brain), adrenal glands, bones, lungs, liver, and digestive tract. These metastases may cause a series of clinical symptoms and seriously affect the patient's quality of life and survival. Brain metastasis is a particular concern after crizotinib resistance. When patients develop brain metastases, they may experience neurological symptoms such as headaches and dizziness. In addition, nausea, vomiting, and loss of appetite are also common manifestations of increased intracranial pressure. The appearance of these symptoms indicates that the condition may have progressed to a more serious stage.

The mechanisms of crizotinib resistance are complex and diverse, and may be related to individual differences in patient absorption, distribution, metabolism, and excretion of the drug. For example, insufficient drug dosage, drug penetration barriers in tumor tissues, and multi-drug resistance mechanisms inside and outside tumor cells may be the causes of drug resistance. The existence of these factors enables tumor cells to escape the killing effect of drugs and continue to proliferate and metastasize.

Therefore, when using crizotinib for treatment, doctors need to closely monitor changes in the patient's condition and promptly detect and deal with drug resistance problems. Once a patient is found to have signs of drug resistance, such as an increase in tumor markers or progression of disease on imaging examinations, the treatment plan should be adjusted in a timely manner. This may include strategies such as switching to other effective targeted drugs, combination chemotherapy or radiotherapy to deal with drug resistance.